

## INVITAE REQUISITION FORM



		PATI	ENT INFORMATIO	N								
First name		MI Last na	me		Date of	birth (MM/DD/YYYY)	)					
Biological sex MRN (medical record num	ber)	Ancestry  O Asian	Black/African American	White/Caucasian O	Ashkenazi Jewish	O Hispanic O N	lative American					
O Female O Pacific Islander O French Canadian O Sephardic Jewish O Mediterranean O Other:												
Email address (for billing contact and repo	ort access after	clinician releases)		Mobile phon	e (for billing conta	ct)						
							للسلسا					
Address												
City State/Prov. 7in/Postal code Country												
City State/Prov Zip/Postal code Country												
Ship a saliva kit to this patient (to subm  Ship kit to address above  Ship kit to			ition form to Invitae Client Ser	vices at 415-276-4164)								
Organization name		CLINI	CAL INFORMATIO	Phone		Fax	•					
Organization name				Thone		Tun						
Address		City	1		State/Prov	ZIP/Postal Code	Country					
		(	CLINICAL TEAM									
Primary clinical contact (contact for general	al inquires)											
Name		NPI	Email address (f	or report access)								
Ordering provider Same as prim	ary clinical coi	ntact	<u>'</u>									
For your convenience, we have provided mult  Name	ple fields belo	w to pre-populate your org	ganization's provider list. For e		ordering provider.							
O Name		N. I		, , , , , , , , , , , , , , , , , , ,								
O Name		NPI	Email address (fo	or report access)								
O Name		NPI	Email address (fo	or report access)								
O Name		NPI	Email address (fo	or report access)								
Name		NPI	Email address (fo	or report access)	ess)							
Additional clinical or laboratory contacts	(optional: sha	re online access to this or	der with the contacts below)									
Share this order with the primary clinical			<u> </u>	ww.invitae.com/signin)								
Name	Email addre	ess (for report access)	Name		Email ad	Email address (for report access)						
Name	Email addre	ess (for report access)	Name		Email ad	Email address (for report access)						
INSURANCE BILLING (att			•				41.4114					
Attach clinical notes, medical records, and/or Policyholder name		al necessity (LMN) to prev Patient relationship to poli	<u> </u>	insurance for certain te	sts <i>or</i> patients outs	Medicare insurance b	, ,					
,		Self Spouse C	Child Other:			(select one):	,					
Primary insurance company name		Primary member ID#	Primary insurance	phone Prior-autho	rization #	Patient was treated as a hospital inpatient (more than a 24 hour						
Secondary insurance company name		Secondary member ID#	Secondary insuran	ce phone Prior-autho	Prior-authorization # stay) in the last 14 days  Not a hospital patient							
PATIENT PAY BILLING		• INSTITU	JTIONAL BILLING		PARTNERSI	HIP PROGRAN	4S					

Invitae partner code:

Invitae will send an invoice to the organization

address above. Please contact Invitae if this order should be billed to a different location.

Invitae will send an electronic invoice to the patient

email listed above. Insurance will not be billed.



Patient's first name

							s	IMPLIFIED R	EQUISITIO	N FORM				
			SPECIMEN INFO	RMATIC	ON									
Label each tube with the pa	tient's full	name, date of bi	rth, and specimen collection date. A requisition fo	rm MUST a	ccompany e	ach specime	n. www.invit	ae.com/specime	n-requirement	S				
Collection date (MM/E	DD/YYYY)		Specimen type:	nts with	Special cases  O History of/current hematologic malignancy  O Resubmission									
If not provided, date wil receipt of specimen.	l be 1 day p	prior to our	allogeneic bone marrow transplants or a blood trai <2 weeks prior to specimen collection.	nsfusion	Is this par	ient decease	d? Dece	eased date (MM/	DD/YYYY)					
Label each tube with the patient's full name, date of birth, and specimen collection date. A requisition  Collection date (MM/DD/YYYY)  If not provided, date will be 1 day prior to our receipt of specimen.  Specimen ID (IB # found on tube) - optional:  PATIENT PERSONAL HISTORY OF CANCER & OTHER CLINICAL INFORMATION (select all that apply)  No personal history of cancer  Patient has been diagnosed with:  DESTINATION (Triple negative breast cancer: ER-, PR-, Her2-)  DESTINATION (Invasive ductal carcinoma)  ILC (invasive ductal carcinoma)  ILC (invasive lobular carcinoma)  Bilateral (two separate breast primaries)  DESTINATION (INFORMATION (INFORMATION)  OFFICIAL CONTROL (Invasive ductal carcinoma)  OFFICI														
PATIEN OTHER CLII	IT PER NICAL	SONAL H INFORM <i>A</i>	ISTORY OF CANCER & ATION (select all that apply)					RY OF CAN that apply)	ICER					
O No personal history of	cancer			0	No known fa	mily history o	of cancer							
		Additional in	nformation			y structure ( ond 45 years		vo 1st- or 2nd-de :her lineage)	gree female re	latives				
		O TNBC (tr	iple negative breast cancer: ER-, PR-, Her2-)	O P	O Patient is adopted									
		O DCIS (du	asive ductal carcinoma)	Relati to pat	ionship tient	Maternal	Paternal	Cancer site		Age at diag- nosis*				
		,	,			0	0							
- '			MSI-high or IHC abnormal			0	0							
Ovarian/Fallopian tube/primary				_		0	0							
		0		-		0	0							
O Prostate cancer						0	0							
O Pancreatic cancer						PR	EVIOUS	RESULTS						
O Colon/rectal cancer			MSI-high or IHC abnormal											
O Colon/rectal polyps		0 1–9	plyp#:	_										
Other cancer	ICD-10 CODES													
Check if applicable to patier % on one of the  Bone marrow transpla	Lynch synd		els (PREMM1,2,6, MMRpro, or MMRpredict)											
* Or first diagnosis if bilatera				<del>-</del>										
								_						

Patient's last name

To request a complimentary specimen collection kit visit www.invitae.com/request-a-kit

## SHIPPING INSTRUCTIONS

Please ship specimen overnight in insulated containers:

Attn: Invitae Client Services, 1400 16th Street, San Francisco, CA 94103, USA

By signing this form, the medical professional acknowledges that the individual/family member authorized to make decisions for the individual (collectively, the "Patient") has been supplied information regarding and consented to undergo genetic testing, substantially as set forth in Invitae's Informed Consent for Genetic Testing (www.invitae.com/patient-consent), has been informed that Invitae may notify them of clinical updates related to genetic test results (in consultation with the ordering medical professional as indicated), and for orders originating outside the US, has been informed that the Patient's personal information and specimen will be transferred to and processed in the US. The Patient has further been informed and authorizes Invitae Corporation ("Invitae") and its designees to release information concerning testing to their insurer, if applicable, in order to process and/or appeal claims on behalf of the Patient. If a letter of medical necessity (LMN) has not been provided, the medical professional agrees to allow Invitae to transfer the information from this requisition to a LMN and/or other documentation using the medical professional's name as the signature for insurance billing. For amounts received directly, the Patient has agreed to remit payment to Invitae for testing services rendered. I acknowledge that I offered pre-test genetic counseling to the Patient, if required by their insurer. In addition to the above, I attest that I am the ordering physician, or I am authorized by the ordering physician to order this test, or I am authorized under applicable law to order this test.

Medical professional signature	Date

**INVITAE HEREDITARY CANCER** 



Patient's first name	Patient's last name	HEREDITARY CANCER SIMPLIFIED
		FM174-3

## HEREDITARY CANCER SIMPLIFIED TEST CATALOG

All tests on this form fall into a single clinical area. If your order contains tests from multiple clinical areas, you will need to send in two sample tubes and your order will represent two billable events. Your test results will be delivered as two reports. Contact Client Services with questions. For Invitae's full test menu, visit www.invitae.com.

INSTRUCTIONS: Indicate your test selection below. Test IDs containing add-on codes will include the genes in both the original test code as well as the add-on code.																			
Test c	ode	Test na	me						# gene(s	(s) Gene list									
STAT	Turi	narou	nd Ti	me															
receiv	red. Ge	enes ca	nnot	be removed	and th	AT PANEL ey cannot be s not accepte	ordere	•	-					•		•			
O 50	0001	Invitae	Breas	t Cancer STA	T Pane	·l			7	BRCA1, I	BRCA2,	, CDH1, PALE	32, PTE	EN, STK11, TF	253				
	○ 50001.1 Add-on ATM gene						1	ATM											
		O 5000	01.2	Add-on CH	EK2 ge	ne			1	CHEK2									
O 50	0002	Invitae	BRCA	1 and BRCA2	2 STAT	Panel			2	BRCA1, BRCA2									
Test c	ode	Test na	me						# gene(s	) Gene list									
Freq	uentl	ly Ord	ered	Hereditar	y Can	cer Panels													
O 01	101	<u> </u>							84	CASR, CI DICER1, KIT, MAX NF2, NT PTCH1, SDHAF2	AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA DICER1, DIS3L2, EGFR, EPCAM, FH, FLCN, GATA2, GPC3, GREM1, HOXB13, HRAS, KIT, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1								
O 01	102	P. Invitae Common Hereditary Cancers Panel  ▶ Reflex to this panel  ○ Regardless of initial results  ○ Only if negative  (no pathogenic/likely pathogenic results)								APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, CTNNA1, DICER1, EPCAM, GREM1, HOXB13, KIT, MEN1, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PDGFRA, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SDHA, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TP53, TSC1, TSC2, VHL									
O 01	206	Invitae	Breas	t Cancer Gui	delines	-Based Panel			11	ATM, BRCA1, BRCA2, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, TP53									
		0120	06.1	Add-on gen	e with	emerging dat	a		1	BARD1									
O 01	204	Invitae	Breas	t and Gyn Ca	incers (	Guidelines-Ba	sed Pa	ınel	19	ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53									
		0120	04.1	Add-on gen	e with	emerging dat	a		1	BARDI									
O 01	252	Invitae	Color	ectal Cancer	Guidel	ines-Based Pa	anel		19	APC, AXIN2, BMPR1A, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53									
		O 012	52.1	Add-on gen	e with	emerging dat	a		1	RPS20									
O 01	701	Invitae Hereditary Breast and Ovarian Cancer Syndrome Panel								BRCA1, BRCA2									
O 01	702	Invitae	Lynch	Syndrome P	anel				5	EPCAM, MLH1, MSH2, MSH6, PMS2									
HEREDITARY CANCER SIMPLIFIED INDIVIDUAL GENES																			
0	APC		0	BRCA1	0	CHEK2	0	HOXB13		MSH6	0	PDGFRA	0	RAD50	0	SDHB	0	STK11	
0	ATM		0	BRCA2	0	CTNNA1	0	KIT	0	MUTYH	0	PMS2	0	RAD51C	0	SDHC	0	TP53	
0	AXIN	12	0	BRIP1	0	DICER1	0	MEN1	0	NBN	0	POLD1	0	RAD51D	0	SDHD	0	TSC1	
0	BARE	D1	0	CDH1	0	EPCAM	0	MLH1		NF1	0	POLE	0	RPS20	0	SMAD4	0	TSC2	
0	BLM				_	NTHL1	0	POT1	0	SDHA	0	SMARCA4	0	VHL					
0	BMP	R1A	0	CDK4	0	GREM1	0	MSH3	0	PALB2	0	PTEN							

Invitae continually updates its panels based on the most recent evidence. Please note that if an order is placed using an older version of this form, Invitae reserves the right to upgrade any ordered panel(s) to the current version(s). To avoid confusion, please consider placing your order using our online test catalog.